Angela C Garinis1, Campbell P Cross2, Priya Srikanth3, Kelly Carroll4, M Patrick Feeney5, Douglas H Keefe6, Lisa L Hunter7, Daniel B Putterman5, David M Cohen8, Jeffrey A Gold9, Peter S Steyger4. 1. Otolaryngology, Oregon Health & Science University, Portland, OR, United States; National Center for Rehabilitative Auditory Research, VA Portland Health Care System, Portland, OR, United States. Electronic address: garinis@ohsu.edu. 2. Otolaryngology, Oregon Health & Science University, Portland, OR, United States; School of Medicine, Oregon Health & Science University, Portland, OR, United States. 3. Public Health & Preventive Medicine, Oregon Health & Science University, Portland, OR, United States. 4. Otolaryngology, Oregon Health & Science University, Portland, OR, United States. 5. Otolaryngology, Oregon Health & Science University, Portland, OR, United States; National Center for Rehabilitative Auditory Research, VA Portland Health Care System, Portland, OR, United States. 6. Boys Town National Research Hospital, Omaha, NE, United States. 7. Cincinnati Children's Hospital, Cincinnati, OH, United States. 8. Nephrology, Oregon Health & Science University, Portland, OR, United States. 9. Pulmonology, Oregon Health & Science University, Portland, OR, United States.
Abstract
BACKGROUND: Aminoglycosides (AGs) and glycopeptides are antibiotics essential for treating life-threatening respiratory infections in patients with cystic fibrosis (CF). The goal of this study was to examine the effects of cumulative intravenous (IV)-AG (amikacin and/or tobramycin) and/or glycopeptide (vancomycin) dosing on hearing status in patients with CF. METHODS: Hearing thresholds were measured from 0.25 to 16.0kHz, in 81 participants with CF. Participants were categorized into two groups: normal hearing in both ears (≤25dB HL for all frequency bands) or hearing loss (>25dB HL for any frequency band in either ear). Participants were also characterized into quartiles by their cumulative IV-AG (with or without vancomycin) exposure. Dosing was calculated using two strategies: (i) total number of lifetime doses, and (ii) total number of lifetime doses while accounting for the total doses per day. This was referred to as the "weighted" method. RESULTS: Participants in the hearing loss group were significantly older than those in the normal-hearing group. After adjusting for gender and age at the time of hearing test, participants in the two highest-quartile exposure groups were almost 5 X more likely to have permanent sensorineural hearing loss than those in the two lowest-quartile exposure groups. There was a small group of CF patients who had normal hearing despite high exposure to IV-antibiotics. CONCLUSIONS: Cumulative IV-antibiotic dosing has a significant negative effect on hearing sensitivity in patients with CF, when controlling for age and gender effects. A trend for increasing odds of hearing loss was associated with increasing cumulative IV-antibiotic dosing.
BACKGROUND:Aminoglycosides (AGs) and glycopeptides are antibiotics essential for treating life-threatening respiratory infections in patients with cystic fibrosis (CF). The goal of this study was to examine the effects of cumulative intravenous (IV)-AG (amikacin and/or tobramycin) and/or glycopeptide (vancomycin) dosing on hearing status in patients with CF. METHODS: Hearing thresholds were measured from 0.25 to 16.0kHz, in 81 participants with CF. Participants were categorized into two groups: normal hearing in both ears (≤25dB HL for all frequency bands) or hearing loss (>25dB HL for any frequency band in either ear). Participants were also characterized into quartiles by their cumulative IV-AG (with or without vancomycin) exposure. Dosing was calculated using two strategies: (i) total number of lifetime doses, and (ii) total number of lifetime doses while accounting for the total doses per day. This was referred to as the "weighted" method. RESULTS:Participants in the hearing loss group were significantly older than those in the normal-hearing group. After adjusting for gender and age at the time of hearing test, participants in the two highest-quartile exposure groups were almost 5 X more likely to have permanent sensorineural hearing loss than those in the two lowest-quartile exposure groups. There was a small group of CF patients who had normal hearing despite high exposure to IV-antibiotics. CONCLUSIONS: Cumulative IV-antibiotic dosing has a significant negative effect on hearing sensitivity in patients with CF, when controlling for age and gender effects. A trend for increasing odds of hearing loss was associated with increasing cumulative IV-antibiotic dosing.
Authors: Luciana M N Martins; Paulo A M Camargos; Helena M G Becker; Celso G Becker; Roberto E S Guimarães Journal: Int J Pediatr Otorhinolaryngol Date: 2010-03-01 Impact factor: 1.675
Authors: F R Bruniera; F M Ferreira; L R M Saviolli; M R Bacci; D Feder; M da Luz Gonçalves Pedreira; M A Sorgini Peterlini; L A Azzalis; V B Campos Junqueira; F L A Fonseca Journal: Eur Rev Med Pharmacol Sci Date: 2015-02 Impact factor: 3.507
Authors: Jeany M Rademaker-Lakhai; Mirjam Crul; Lot Zuur; Paul Baas; Jos H Beijnen; Yvonne J W Simis; Nico van Zandwijk; Jan H M Schellens Journal: J Clin Oncol Date: 2006-02-20 Impact factor: 44.544
Authors: Douglas H Keefe; M Patrick Feeney; Lisa L Hunter; Denis F Fitzpatrick; Chelsea M Blankenship; Angela C Garinis; Daniel B Putterman; Marcin Wróblewski Journal: Hear Res Date: 2018-10-18 Impact factor: 3.208
Authors: Angela C Garinis; Douglas H Keefe; Lisa L Hunter; Denis F Fitzpatrick; Daniel B Putterman; Garnett P McMillan; Jeffrey A Gold; M Patrick Feeney Journal: Ear Hear Date: 2018 Jan/Feb Impact factor: 3.570
Authors: Takahiko Matsushita; Girish C Sati; Nuwan Kondasinghe; Michael G Pirrone; Takayuki Kato; Prabuddha Waduge; Harshitha Santhosh Kumar; Adrian Cortes Sanchon; Malgorzata Dobosz-Bartoszek; Dimitri Shcherbakov; Mario Juhas; Sven N Hobbie; Thomas Schrepfer; Christine S Chow; Yury S Polikanov; Jochen Schacht; Andrea Vasella; Erik C Böttger; David Crich Journal: J Am Chem Soc Date: 2019-03-13 Impact factor: 15.419
Authors: Min Dong; Anna V Rodriguez; Chelsea A Blankenship; Gary McPhail; Alexander A Vinks; Lisa L Hunter Journal: J Antimicrob Chemother Date: 2021-10-11 Impact factor: 5.790
Authors: Dawn Konrad-Martin; Gayla L Poling; Angela C Garinis; Candice E Ortiz; Jennifer Hopper; Keri O'Connell Bennett; Marilyn F Dille Journal: Int J Audiol Date: 2017-11-20 Impact factor: 2.117
Authors: Sarwat Chowdhury; Kelly N Owens; R Jason Herr; Qin Jiang; Xinchao Chen; Graham Johnson; Vincent E Groppi; David W Raible; Edwin W Rubel; Julian A Simon Journal: J Med Chem Date: 2017-10-27 Impact factor: 7.446
Authors: Lisa L Hunter; Brian B Monson; David R Moore; Sumitrajit Dhar; Beverly A Wright; Kevin J Munro; Lina Motlagh Zadeh; Chelsea M Blankenship; Samantha M Stiepan; Jonathan H Siegel Journal: Hear Res Date: 2020-02-18 Impact factor: 3.208